DATA AND SAFETY MONITORING The Data and Safety Monitoring Plan (DSMP) of the Kimmel Cancer Center (KCC) provides for the oversight and monitoring of clinical trials to ensure the: 1. Safety of patients;and 2. Validity and integrity of the data collected on these trials. Responsibility for data and safety monitoring at Thomas Jefferson University (TJU) resides in: 1. The Clinical Cancer Research Review Committee (CCRRC) which oversees the scientific review of all new and ongoing cancer-related clinical trials within the KCC; 2. The Clinical Research Management Office (CRMO) which provides strategic assistance and support to the CCRRC, DSMC, and continuous monitoring; 3. The Institutional Review Board (IRB) which has primary responsibility for the protection of the welfare of human subjects involved in biomedical and behavioral research. The IRB has full authority to approve, request modifications prior to approval, disapprove, suspend, or terminate for cause all research activities that fall within its jurisdiction;and 4. The Data and Safety Monitoring Committee (DSMC), which is responsible for data and safety monitoring of Kimmel Cancer Center investigator-initiated trials (KCC IIT).

Public Health Relevance

The DSMP requires that every Kimmel Cancer Center protocol include a data and safefy monitoring plan. The CCRRC will not review a study that does not have such a plan, and the TJU IRB will not accept a study for review and approval until it has been approved by the CCRRC

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Thomas Jefferson University
United States
Zip Code
Li, Jifen; Gao, Erhe; Vite, Alexia et al. (2015) Alpha-catenins control cardiomyocyte proliferation by regulating Yap activity. Circ Res 116:70-9
Basile, Kevin J; Le, Kaitlyn; Hartsough, Edward J et al. (2014) Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res 27:479-84
Sonar, Mahesh V; Wampole, Matthew E; Jin, Yuan-Yuan et al. (2014) Fluorescence detection of KRAS2 mRNA hybridization in lung cancer cells with PNA-peptides containing an internal thiazole orange. Bioconjug Chem 25:1697-708
Gu, Lei; Talati, Pooja; Vogiatzi, Paraskevi et al. (2014) Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther 13:1246-58
Bhardwaj, Anshul; Casjens, Sherwood R; Cingolani, Gino (2014) Exploring the atomic structure and conformational flexibility of a 320?Å long engineered viral fiber using X-ray crystallography. Acta Crystallogr D Biol Crystallogr 70:342-53
Siciliano, Nicholas A; Hersperger, Adam R; Lacuanan, Aimee M et al. (2014) Impact of distinct poxvirus infections on the specificities and functionalities of CD4+ T cell responses. J Virol 88:10078-91
Clark, Peter M; Loher, Phillipe; Quann, Kevin et al. (2014) Argonaute CLIP-Seq reveals miRNA targetome diversity across tissue types. Sci Rep 4:5947
Li, Yuan; Liang, Chunli; Ma, Haizhong et al. (2014) miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules 19:7122-37
Wilson, Chantell; Lin, Jieru E; Li, Peng et al. (2014) The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. Cancer Epidemiol Biomarkers Prev 23:2328-37
Khasnis, Mukta; Nakatomi, Akiko; Gumpper, Kristyn et al. (2014) Reconstituted human myosin light chain phosphatase reveals distinct roles of two inhibitory phosphorylation sites of the regulatory subunit, MYPT1. Biochemistry 53:2701-9

Showing the most recent 10 out of 343 publications